The epidermal growth factor receptor: A role in repair of radiation-induced DNA damage

被引:155
作者
Chen, David J. [1 ]
Nirodi, Chaitanya S. [1 ]
机构
[1] Univ Texas SW Med Ctr, Dept Radiat Oncol, Div Mol Radiat Biol, Dallas, TX 75390 USA
关键词
D O I
10.1158/1078-0432.CCR-07-1610
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
The epidermal growth factor receptor (EGFR), which is frequently expressed in tumors of epithelial origin, is an important determinant of tumor responses to ionizing radiation. Elevated EGFR expression and activity frequently correlate with tumor resistance to radiotherapy in patients. EGFR is thought to confer tumor resistance to radiation through the activation of survival and cell proliferation pathways. Recent discoveries have identified a novel radioprotective function of EGFR which involves the radiation-induced nuclear translocation of the receptor and its interactions with the DNA-dependent protein kinase, a key component of the nonhomologous end-joining DNA repair pathway. Targeting the DNA repair function of EGFR may serve as a therapeutic model for sensitizing tumors to radiotherapy in patients.
引用
收藏
页码:6555 / 6560
页数:6
相关论文
共 76 条
[1]
Akimoto T, 1999, CLIN CANCER RES, V5, P2884
[2]
Amann J, 2005, CANCER RES, V65, P226
[3]
Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474 [J].
Arao, T ;
Fukumoto, H ;
Takeda, M ;
Tamura, T ;
Saijo, N ;
Nishio, K .
CANCER RESEARCH, 2004, 64 (24) :9101-9104
[4]
Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells [J].
Bandyopadhyay, D ;
Mandal, M ;
Adam, L ;
Mendelsohn, J ;
Kumar, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (03) :1568-1573
[5]
EGFR-targeted anti-cancer drugs in radiotherapy:: Preclinical evaluation of mechanisms [J].
Baumann, Michael ;
Krause, Mechthild ;
Dikomey, Ekkehard ;
Dittmann, Klaus ;
Doerr, Wolfgang ;
Kasten-Pisula, Ulla ;
Rodemann, H. Peter .
RADIOTHERAPY AND ONCOLOGY, 2007, 83 (03) :238-248
[6]
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials [J].
Bell, DW ;
Lynch, TJ ;
Haserlat, SM ;
Harris, PL ;
Okimoto, RA ;
Brannigan, BW ;
Sgroi, DC ;
Muir, B ;
Riemenschneider, MJ ;
Iacona, RB ;
Krebs, AD ;
Johnson, DH ;
Giaccone, G ;
Herbst, RS ;
Manegold, C ;
Fukuoka, M ;
Kris, MG ;
Baselga, J ;
Ochs, JS ;
Haber, DA .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) :8081-8092
[7]
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies [J].
Benvenuti, Silvia ;
Sartore-Bianchi, Andrea ;
Di Nicolantonio, Federica ;
Zanon, Carlo ;
Moroni, Mauro ;
Veronese, Silvio ;
Siena, Salvatore ;
Bardelli, Alberto .
CANCER RESEARCH, 2007, 67 (06) :2643-2648
[8]
Identification of a nonsense mutation in the carboxyl-terminal region of DNA-dependent protein kinase catalytic subunit in the scid mouse [J].
Blunt, T ;
Gell, D ;
Fox, M ;
Taccioli, GE ;
Lehmann, AR ;
Jackson, SP ;
Jeggo, PA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (19) :10285-10290
[9]
DEFECTIVE DNA-DEPENDENT PROTEIN-KINASE ACTIVITY IS LINKED TO V(D)J RECOMBINATION AND DNA-REPAIR DEFECTS ASSOCIATED WITH THE MURINE SCID MUTATION [J].
BLUNT, T ;
FINNIE, NJ ;
TACCIOLI, GE ;
SMITH, GCM ;
DEMENGEOT, J ;
GOTTLIEB, TM ;
MIZUTA, R ;
VARGHESE, AJ ;
ALT, FW ;
JEGGO, PA ;
JACKSON, SP .
CELL, 1995, 80 (05) :813-823
[10]
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck [J].
Bonner, JA ;
Harari, PM ;
Giralt, J ;
Azarnia, N ;
Shin, DM ;
Cohen, RB ;
Jones, CU ;
Sur, R ;
Raben, D ;
Jassem, J ;
Ove, R ;
Kies, MS ;
Baselga, J ;
Youssoufian, H ;
Amellal, N ;
Rowinsky, EK ;
Ang, KK .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) :567-578